Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Arcellx, Inc. (NASDAQ:ACLX – Free Report) by 34.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,811 shares of the company’s stock after buying an additional 1,740 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Arcellx were worth $376,000 as of its most recent SEC filing.
A number of other large investors also recently bought and sold shares of the business. Plato Investment Management Ltd purchased a new stake in shares of Arcellx during the first quarter valued at about $51,000. Advisory Alpha LLC acquired a new stake in Arcellx in the first quarter valued at approximately $209,000. Simplicity Wealth LLC purchased a new position in Arcellx in the first quarter worth $232,000. Bleakley Financial Group LLC acquired a new position in shares of Arcellx during the first quarter worth $232,000. Finally, Advisors Asset Management Inc. increased its position in shares of Arcellx by 951.9% during the first quarter. Advisors Asset Management Inc. now owns 4,197 shares of the company’s stock worth $292,000 after purchasing an additional 3,798 shares in the last quarter. Institutional investors own 96.03% of the company’s stock.
Insiders Place Their Bets
In other news, insider Christopher Heery sold 27,451 shares of Arcellx stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $67.03, for a total transaction of $1,840,040.53. Following the completion of the transaction, the insider now directly owns 9,278 shares of the company’s stock, valued at approximately $621,904.34. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Arcellx news, CFO Michelle Gilson sold 12,877 shares of the stock in a transaction that occurred on Wednesday, June 26th. The stock was sold at an average price of $53.70, for a total transaction of $691,494.90. Following the transaction, the chief financial officer now owns 6,915 shares in the company, valued at $371,335.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Christopher Heery sold 27,451 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $67.03, for a total value of $1,840,040.53. Following the completion of the sale, the insider now directly owns 9,278 shares in the company, valued at $621,904.34. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 133,005 shares of company stock worth $8,176,372. Corporate insiders own 6.24% of the company’s stock.
Wall Street Analysts Forecast Growth
Get Our Latest Report on Arcellx
Arcellx Price Performance
NASDAQ ACLX opened at $71.25 on Friday. Arcellx, Inc. has a 1 year low of $30.88 and a 1 year high of $75.10. The company has a market capitalization of $3.81 billion, a PE ratio of -69.17 and a beta of 0.23. The company has a fifty day moving average of $61.95 and a 200 day moving average of $59.79.
Arcellx (NASDAQ:ACLX – Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.01. The business had revenue of $27.38 million during the quarter, compared to analysts’ expectations of $22.04 million. Arcellx had a negative return on equity of 12.42% and a negative net margin of 37.23%. The company’s revenue for the quarter was up 91.5% on a year-over-year basis. Research analysts expect that Arcellx, Inc. will post -1.64 earnings per share for the current year.
About Arcellx
Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).
Recommended Stories
- Five stocks we like better than Arcellx
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Is Merck Stock Undervalued After Its Colossal Earnings Growth?
- What Investors Need to Know to Beat the Market
- Top 5 ETFs for Every Investor: From Semiconductors to Defense
- Stock Splits, Do They Really Impact Investors?
- Blade Air Mobility: This Under-the-Radar Stock Could Double Soon
Want to see what other hedge funds are holding ACLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arcellx, Inc. (NASDAQ:ACLX – Free Report).
Receive News & Ratings for Arcellx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcellx and related companies with MarketBeat.com's FREE daily email newsletter.